Cadila Healthcare Ltd., incorporated in the year 1995, is a Large Cap company (having a market cap of Rs 57713.49 Crore) operating in Pharmaceuticals sector.
Financials
For the quarter ended 30-06-2021, the company reported a Consolidated Total Income of Rs 4057.00 Crore, up 6.58 % from last quarter Total Income of Rs 3806.40 Crore and up 10.77 % from last year same quarter Total Income of Rs 3662.40 Crore. Company reported net profit after tax of Rs 635.50 Crore in latest quarter.
Investment Rationale
The brokerage expects 12% earnings CAGR on the back of 16% sales CAGR in DF (considering the muted growth in FY21) and steady US sales (despite increased competition), aided by an 110bp margin expansion from new initiatives in manufacturing, and reduced financial leverage. The vaccine opportunity in India is not built into estimates and can provide a further upside, post approval. The brokerage maintains Buy rating.
Promoter/FII Holdings
Promoters held 74.9 per cent stake in the company as of June 30, 2021, while FIIs held 4.7 per cent, DIIs 10.6 per cent and public and others 9.9 per cent.
(Disclaimer: Views and recommendations given in this section are the analysts’ own and do not represent those of ETMarkets.com. Please consult your financial adviser before taking any position in the stock/s mentioned.
